Clinical results for patients with major depressive disorder in the Texas medication algorithm project

Madhukar H. Trivedi, A. John Rush, M. Lynn Crismon, T. Michael Kashner, Marcia G. Toprac, Thomas J. Carmody, Tracie Key, Melanie M. Biggs, Kathy Shores-Wilson, Bradley Witte, Trisha Suppes, Alexander L. Miller, Kenneth Z. Altshuler, Steven P. Shon

Research output: Contribution to journalArticle

232 Citations (Scopus)

Abstract

Context: The Texas Medication Algorithm Project is an evaluation of an algorithm-based disease management program for the treatment of the self-declared persistently and seriously mentally ill in the public mental health sector. Objective: To present clinical outcomes for patients with major depressive disorder (MDD) during 12-month algorithm-guided treatment (ALGO) compared with treatment as usual (TAU). Design: Effectiveness, intent-to-treat, prospective trial comparing patient outcomes in clinics offering ALGO with matched clinics offering TAU. Setting: Four ALGO clinics, 6 TAU clinics, and 4 clinics that offer TAU to patients with MDD but provide ALGO for schizophrenia or bipolar disorder. Patients: Male and female outpatients with a clinical diagnosis of MDD (psychotic or nonpsychotic) were divided into ALGO and TAU groups. The ALGO group included patients who required an antidepressant medication change or were starting antidepressant therapy. The TAU group initially met the same criteria, but because medication changes were made less frequently in the TAU group, patients were also recruited if their Brief Psychiatric Rating Scale total score was higher than the median for that clinic's routine quarterly evaluation of each patient. Maim Outcome Measures: Primary outcomes included (1) symptoms measured by the 30-item Inventory of Depressive Symptomatology-Clinician-Rated scale (IDS-C30) and (2) function measured by the Mental Health Summary score of the Medical Outcomes Study 12-item Short-Form Health Survey (SF-12) obtained every 3 months. A secondary outcome was the 30-item Inventory of Depressive Symptomatology-Self- Report scale (IDS-SR30). Results: All patients improved during the study (P<.001), but ALGO patients had significantly greater symptom reduction on both the IDS-C30 and IDS-SR30 compared with TAU. ALGO was also associated with significantly greater improvement in the SF-12 mental health score (P=.046) than TAU. Conclusion: The ALGO intervention package during 1 year was superior to TAU for patients with MDD based on clinician-rated and self-reported symptoms and overall mental functioning.

Original languageEnglish (US)
Pages (from-to)669-680
Number of pages12
JournalArchives of General Psychiatry
Volume61
Issue number7
DOIs
StatePublished - Jul 2004

Fingerprint

Major Depressive Disorder
Therapeutics
Mental Health
Antidepressive Agents
Outcome Assessment (Health Care)
Brief Psychiatric Rating Scale
Equipment and Supplies

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Clinical results for patients with major depressive disorder in the Texas medication algorithm project. / Trivedi, Madhukar H.; Rush, A. John; Crismon, M. Lynn; Kashner, T. Michael; Toprac, Marcia G.; Carmody, Thomas J.; Key, Tracie; Biggs, Melanie M.; Shores-Wilson, Kathy; Witte, Bradley; Suppes, Trisha; Miller, Alexander L.; Altshuler, Kenneth Z.; Shon, Steven P.

In: Archives of General Psychiatry, Vol. 61, No. 7, 07.2004, p. 669-680.

Research output: Contribution to journalArticle

Trivedi, Madhukar H. ; Rush, A. John ; Crismon, M. Lynn ; Kashner, T. Michael ; Toprac, Marcia G. ; Carmody, Thomas J. ; Key, Tracie ; Biggs, Melanie M. ; Shores-Wilson, Kathy ; Witte, Bradley ; Suppes, Trisha ; Miller, Alexander L. ; Altshuler, Kenneth Z. ; Shon, Steven P. / Clinical results for patients with major depressive disorder in the Texas medication algorithm project. In: Archives of General Psychiatry. 2004 ; Vol. 61, No. 7. pp. 669-680.
@article{8e46657f82a54084826115ef17b15dc2,
title = "Clinical results for patients with major depressive disorder in the Texas medication algorithm project",
abstract = "Context: The Texas Medication Algorithm Project is an evaluation of an algorithm-based disease management program for the treatment of the self-declared persistently and seriously mentally ill in the public mental health sector. Objective: To present clinical outcomes for patients with major depressive disorder (MDD) during 12-month algorithm-guided treatment (ALGO) compared with treatment as usual (TAU). Design: Effectiveness, intent-to-treat, prospective trial comparing patient outcomes in clinics offering ALGO with matched clinics offering TAU. Setting: Four ALGO clinics, 6 TAU clinics, and 4 clinics that offer TAU to patients with MDD but provide ALGO for schizophrenia or bipolar disorder. Patients: Male and female outpatients with a clinical diagnosis of MDD (psychotic or nonpsychotic) were divided into ALGO and TAU groups. The ALGO group included patients who required an antidepressant medication change or were starting antidepressant therapy. The TAU group initially met the same criteria, but because medication changes were made less frequently in the TAU group, patients were also recruited if their Brief Psychiatric Rating Scale total score was higher than the median for that clinic's routine quarterly evaluation of each patient. Maim Outcome Measures: Primary outcomes included (1) symptoms measured by the 30-item Inventory of Depressive Symptomatology-Clinician-Rated scale (IDS-C30) and (2) function measured by the Mental Health Summary score of the Medical Outcomes Study 12-item Short-Form Health Survey (SF-12) obtained every 3 months. A secondary outcome was the 30-item Inventory of Depressive Symptomatology-Self- Report scale (IDS-SR30). Results: All patients improved during the study (P<.001), but ALGO patients had significantly greater symptom reduction on both the IDS-C30 and IDS-SR30 compared with TAU. ALGO was also associated with significantly greater improvement in the SF-12 mental health score (P=.046) than TAU. Conclusion: The ALGO intervention package during 1 year was superior to TAU for patients with MDD based on clinician-rated and self-reported symptoms and overall mental functioning.",
author = "Trivedi, {Madhukar H.} and Rush, {A. John} and Crismon, {M. Lynn} and Kashner, {T. Michael} and Toprac, {Marcia G.} and Carmody, {Thomas J.} and Tracie Key and Biggs, {Melanie M.} and Kathy Shores-Wilson and Bradley Witte and Trisha Suppes and Miller, {Alexander L.} and Altshuler, {Kenneth Z.} and Shon, {Steven P.}",
year = "2004",
month = "7",
doi = "10.1001/archpsyc.61.7.669",
language = "English (US)",
volume = "61",
pages = "669--680",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Clinical results for patients with major depressive disorder in the Texas medication algorithm project

AU - Trivedi, Madhukar H.

AU - Rush, A. John

AU - Crismon, M. Lynn

AU - Kashner, T. Michael

AU - Toprac, Marcia G.

AU - Carmody, Thomas J.

AU - Key, Tracie

AU - Biggs, Melanie M.

AU - Shores-Wilson, Kathy

AU - Witte, Bradley

AU - Suppes, Trisha

AU - Miller, Alexander L.

AU - Altshuler, Kenneth Z.

AU - Shon, Steven P.

PY - 2004/7

Y1 - 2004/7

N2 - Context: The Texas Medication Algorithm Project is an evaluation of an algorithm-based disease management program for the treatment of the self-declared persistently and seriously mentally ill in the public mental health sector. Objective: To present clinical outcomes for patients with major depressive disorder (MDD) during 12-month algorithm-guided treatment (ALGO) compared with treatment as usual (TAU). Design: Effectiveness, intent-to-treat, prospective trial comparing patient outcomes in clinics offering ALGO with matched clinics offering TAU. Setting: Four ALGO clinics, 6 TAU clinics, and 4 clinics that offer TAU to patients with MDD but provide ALGO for schizophrenia or bipolar disorder. Patients: Male and female outpatients with a clinical diagnosis of MDD (psychotic or nonpsychotic) were divided into ALGO and TAU groups. The ALGO group included patients who required an antidepressant medication change or were starting antidepressant therapy. The TAU group initially met the same criteria, but because medication changes were made less frequently in the TAU group, patients were also recruited if their Brief Psychiatric Rating Scale total score was higher than the median for that clinic's routine quarterly evaluation of each patient. Maim Outcome Measures: Primary outcomes included (1) symptoms measured by the 30-item Inventory of Depressive Symptomatology-Clinician-Rated scale (IDS-C30) and (2) function measured by the Mental Health Summary score of the Medical Outcomes Study 12-item Short-Form Health Survey (SF-12) obtained every 3 months. A secondary outcome was the 30-item Inventory of Depressive Symptomatology-Self- Report scale (IDS-SR30). Results: All patients improved during the study (P<.001), but ALGO patients had significantly greater symptom reduction on both the IDS-C30 and IDS-SR30 compared with TAU. ALGO was also associated with significantly greater improvement in the SF-12 mental health score (P=.046) than TAU. Conclusion: The ALGO intervention package during 1 year was superior to TAU for patients with MDD based on clinician-rated and self-reported symptoms and overall mental functioning.

AB - Context: The Texas Medication Algorithm Project is an evaluation of an algorithm-based disease management program for the treatment of the self-declared persistently and seriously mentally ill in the public mental health sector. Objective: To present clinical outcomes for patients with major depressive disorder (MDD) during 12-month algorithm-guided treatment (ALGO) compared with treatment as usual (TAU). Design: Effectiveness, intent-to-treat, prospective trial comparing patient outcomes in clinics offering ALGO with matched clinics offering TAU. Setting: Four ALGO clinics, 6 TAU clinics, and 4 clinics that offer TAU to patients with MDD but provide ALGO for schizophrenia or bipolar disorder. Patients: Male and female outpatients with a clinical diagnosis of MDD (psychotic or nonpsychotic) were divided into ALGO and TAU groups. The ALGO group included patients who required an antidepressant medication change or were starting antidepressant therapy. The TAU group initially met the same criteria, but because medication changes were made less frequently in the TAU group, patients were also recruited if their Brief Psychiatric Rating Scale total score was higher than the median for that clinic's routine quarterly evaluation of each patient. Maim Outcome Measures: Primary outcomes included (1) symptoms measured by the 30-item Inventory of Depressive Symptomatology-Clinician-Rated scale (IDS-C30) and (2) function measured by the Mental Health Summary score of the Medical Outcomes Study 12-item Short-Form Health Survey (SF-12) obtained every 3 months. A secondary outcome was the 30-item Inventory of Depressive Symptomatology-Self- Report scale (IDS-SR30). Results: All patients improved during the study (P<.001), but ALGO patients had significantly greater symptom reduction on both the IDS-C30 and IDS-SR30 compared with TAU. ALGO was also associated with significantly greater improvement in the SF-12 mental health score (P=.046) than TAU. Conclusion: The ALGO intervention package during 1 year was superior to TAU for patients with MDD based on clinician-rated and self-reported symptoms and overall mental functioning.

UR - http://www.scopus.com/inward/record.url?scp=3042702585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042702585&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.61.7.669

DO - 10.1001/archpsyc.61.7.669

M3 - Article

C2 - 15237079

AN - SCOPUS:3042702585

VL - 61

SP - 669

EP - 680

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 7

ER -